InMode Ltd. (NASDAQ:INMD) is up approximately 11% intraday at $14.83 after the board disclosed an unsolicited take-private proposal from a group including co-founder and CEO Moshe Mizrahy offering $16.20 per share in cash.

Key Highlights

• InMode is up approximately 11% intraday at $14.83 after receiving a take-private proposal at $16.20 per share from M.N. Business Strategy, which includes co-founder and CEO Moshe Mizrahy.

• The $16.20 offer represents a premium of roughly 21% to the pre-announcement price of $13.35; InvestingPro estimates fair value at $19.58 per share.

• The board formed a special committee of independent directors to evaluate the proposal, introducing uncertainty around timeline, competing bids, and final valuation.

• InMode is now an M&A event-driven stock; the operational narrative around medical aesthetics headwinds is secondary to the take-private process outcome.

Insider-Led Take-Private Triggers 11% Intraday Surge

InMode Ltd. (NASDAQ:INMD), a Yokneam, Israel-based medical technology company developing minimally-invasive radiofrequency platforms including BodyTite, FaceTite, and Morpheus8, is up approximately 11% intraday at $14.83. On June 24, the board confirmed receipt of a proposal from M.N. Business Strategy to acquire all outstanding ordinary shares not owned by the group at $16.20 per share in cash. M.N. Business Strategy includes co-founder and CEO Moshe Mizrahy, making this an insider-led take-private attempt. The stock is consolidating near $14.83 as the market digests the offer terms and weighs deal probability.

Offer Terms, Premium, and Special Committee

The $16.20 offer represents approximately a 21% premium to the pre-announcement price of $13.35. InvestingPro's fair value estimate of $19.58 sits roughly 21% above the offer price, providing a natural basis for the special committee to seek improved terms or solicit competing bids.

The board formed a special committee of independent directors to evaluate the proposal with independent financial and legal advisers. Key uncertainties include timeline, whether the committee seeks improved terms, whether third-party competing bids emerge, and whether the committee concludes the offer serves public shareholders' best interests. At the current intraday price of $14.83, the stock trades below the $16.20 offer, reflecting a deal probability discount for these execution risks.

From Operational to Event-Driven

Prior to this disclosure, InMode was an operational story navigating medical aesthetics headwinds from moderating consumer spending on elective procedures and competitive pressure. Those fundamentals remain relevant to the special committee's standalone valuation analysis, but from an investor perspective InMode has transitioned to an event-driven position where near-term price action is driven by the take-private process outcome rather than quarterly aesthetics trends.